{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T22:30:47Z","timestamp":1765233047359,"version":"3.44.0"},"reference-count":258,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Life Sciences"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.lfs.2021.119289","type":"journal-article","created":{"date-parts":[[2021,3,5]],"date-time":"2021-03-05T11:26:45Z","timestamp":1614943605000},"page":"119289","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["The significance of bioengineered nanoplatforms against SARS-CoV-2: From detection to genome editing"],"prefix":"10.1016","volume":"274","author":[{"given":"Parichehr","family":"Hassanzadeh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5168","key":"10.1016\/j.lfs.2021.119289_bb0005","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/220650b0","article-title":"Virology: coronaviruses","volume":"220","author":"Almeida","year":"1968","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.lfs.2021.119289_bb0010","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.3390\/v2081803","article-title":"Coronavirus genomics and bioinformatics analysis","volume":"2","author":"Woo","year":"2010","journal-title":"Viruses"},{"key":"10.1016\/j.lfs.2021.119289_bb0015","article-title":"Identification of 2019-nCoV related coronaviruses in Malayan pangolins in southern China","author":"Lam","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.lfs.2021.119289_bb0020","doi-asserted-by":"crossref","first-page":"3395","DOI":"10.1016\/j.celrep.2019.08.052","article-title":"Structural definition of a neutralization-sensitive epitope on the MERS-CoV S1-NTD","volume":"28","author":"Wang","year":"2019","journal-title":"Cell Rep."},{"key":"10.1016\/j.lfs.2021.119289_bb0025","article-title":"SARS-CoV-2 and SARS-CoV spike-RBD structure and receptor binding comparison and potential implications on neutralizing antibody and vaccine development","author":"Sun","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.lfs.2021.119289_bb0030","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1126\/science.1116480","article-title":"Structure of SARS coronavirus spike receptor-binding domain complexed with receptor","volume":"309","author":"Li","year":"2005","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.lfs.2021.119289_bb0035","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.antiviral.2013.09.028","article-title":"Proteolytic activation of the SARS-coronavirus spike protein: cutting enzymes at the cutting edge of antiviral research","volume":"100","author":"Simmons","year":"2013","journal-title":"Antivir. Res."},{"key":"10.1016\/j.lfs.2021.119289_bb0040","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.celrep.2018.06.041","article-title":"Structural definition of a unique neutralization epitope on the receptor-binding domain of MERS-CoV spike glycoprotein","volume":"24","author":"Zhang","year":"2018","journal-title":"Cell Rep."},{"issue":"11 Suppl","key":"10.1016\/j.lfs.2021.119289_bb0045","article-title":"History and recent advances in coronavirus discovery","volume":"24","author":"Kahn","year":"2005","journal-title":"Pediatr. Infect. Dis. J."},{"issue":"5297","key":"10.1016\/j.lfs.2021.119289_bb0050","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1136\/bmj.2.5297.82","article-title":"Virus isolations from common colds occurring in a residential school","volume":"2","author":"Kendall","year":"1962","journal-title":"Br. Med. J."},{"issue":"6","key":"10.1016\/j.lfs.2021.119289_bb0055","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.tim.2016.03.003","article-title":"Epidemiology, genetic recombination, and pathogenesis of coronaviruses","volume":"24","author":"Su","year":"2016","journal-title":"Trends Microbiol."},{"issue":"8","key":"10.1016\/j.lfs.2021.119289_bb0060","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A novel coronavirus from patients with pneumonia in China, 2019","volume":"382","author":"Zhu","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lfs.2021.119289_bb0065","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/bs.aivir.2018.01.001","article-title":"Hosts and sources of endemic human coronaviruses","volume":"100","author":"Corman","year":"2018","journal-title":"Adv. Virus Res."},{"key":"10.1016\/j.lfs.2021.119289_bb0070","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.ijid.2020.01.009","article-title":"The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health\u2014the latest 2019 novel coronavirus outbreak in Wuhan, China","volume":"91","author":"Hui","year":"2020","journal-title":"Int. J. Infect. Dis."},{"year":"2020","series-title":"Potential Impact of Seasonal Forcing on a SARS-CoV-2 Pandemic. MedRxiv","author":"Neher","key":"10.1016\/j.lfs.2021.119289_bb0075"},{"key":"10.1016\/j.lfs.2021.119289_bb0080","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/s41577-020-0311-8","article-title":"The trinity of COVID-19: immunity, inflammation and intervention","volume":"20","author":"Tay","year":"2020","journal-title":"Nat. Rev. Immunol."},{"year":"2020","series-title":"Coronavirus (COVID-19) Update: Serological Tests","author":"Hahn","key":"10.1016\/j.lfs.2021.119289_bb0085"},{"issue":"5","key":"10.1016\/j.lfs.2021.119289_bb0090","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1021\/acscentsci.0c00501","article-title":"Assay techniques and test development for COVID-19 diagnosis","volume":"6","author":"Carter","year":"2020","journal-title":"ACS Cent Sci"},{"issue":"1","key":"10.1016\/j.lfs.2021.119289_bb0095","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1128\/CMR.19.1.165-256.2006","article-title":"Real-time PCR in clinical microbiology: applications for routine laboratory testing","volume":"19","author":"Espy","year":"2006","journal-title":"Clin. Microbiol. Rev."},{"issue":"3","key":"10.1016\/j.lfs.2021.119289_bb0100","first-page":"155","article-title":"Pitfalls of quantitative real-time reverse-transcription polymerase chain reaction","volume":"15","author":"Bustin","year":"2004","journal-title":"J. Biomol. Tech."},{"key":"10.1016\/j.lfs.2021.119289_bb0105","first-page":"1","article-title":"Real-time RT-PCR in COVID-19 detection: issues affecting the results","author":"Tahamtan","year":"2020","journal-title":"Expert. Rev. Mol. Diagn."},{"key":"10.1016\/j.lfs.2021.119289_bb0110","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1097\/CJI.0b013e31816dad10","article-title":"A multipeptide vaccine is safe and elicits T-cell responses in participants with advanced stage ovarian cancer","volume":"31","author":"Chianese-Bullock","year":"2008","journal-title":"J. Immunother."},{"key":"10.1016\/j.lfs.2021.119289_bb0115","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.febslet.2013.10.014","article-title":"Protein engineering strategies for the development of viral vaccines and immunotherapeutics","volume":"588","author":"Koellhoffer","year":"2014","journal-title":"FEBS Lett."},{"issue":"2","key":"10.1016\/j.lfs.2021.119289_bb0120","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1039\/C5SC03892H","article-title":"Peptide-based synthetic vaccines","volume":"7","author":"Skwarczynski","year":"2016","journal-title":"Chem. Sci."},{"issue":"8","key":"10.1016\/j.lfs.2021.119289_bb0125","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.2147\/DDDT.S67861","article-title":"Design of an epitope-based peptide vaccine against spike protein of human coronavirus: an in silico approach","author":"Oany","year":"2014","journal-title":"Drug Design, Development and Therapy"},{"issue":"6","key":"10.1016\/j.lfs.2021.119289_bb0130","doi-asserted-by":"crossref","first-page":"3210","DOI":"10.1021\/acs.chemrev.9b00472","article-title":"Peptide-based vaccines: current progress and future challenges","volume":"120","author":"Malonis","year":"2020","journal-title":"Chem. Rev."},{"key":"10.1016\/j.lfs.2021.119289_bb0135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2013\/521231","article-title":"Peptide-based vaccinology: experimental and computational approaches to target hypervariable viruses through the fine characterization of protective epitopes recognized by monoclonal antibodies and the identification of T-cell-activating peptides","volume":"2013","author":"Castelli","year":"2013","journal-title":"Clin. Dev. Immunol."},{"issue":"6","key":"10.1016\/j.lfs.2021.119289_bb0140","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1586\/14760584.6.6.939","article-title":"Epitope-based vaccine against influenza","volume":"6","author":"Ben-Yedidia","year":"2007","journal-title":"Expert Review of Vaccines"},{"issue":"1","key":"10.1016\/j.lfs.2021.119289_bb0145","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1099\/vir.0.036640-0","article-title":"A cross-protective mAb recognizes a novel epitope within the flavivirus NS1 protein","volume":"93","author":"Lee","year":"2012","journal-title":"J. Gen. Virol."},{"issue":"1","key":"10.1016\/j.lfs.2021.119289_bb0150","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.antiviral.2011.07.013","article-title":"A potential role for monoclonal antibodies in prophylactic and therapeutic treatment of influenza","volume":"92","author":"Mancini","year":"2011","journal-title":"Antivir. Res."},{"issue":"3","key":"10.1016\/j.lfs.2021.119289_bb0155","doi-asserted-by":"crossref","first-page":"145","DOI":"10.2165\/00063030-200721030-00002","article-title":"Epitope mapping: the first step in developing epitope-based vaccines","volume":"21","author":"Gershoni","year":"2007","journal-title":"BioDrugs"},{"issue":"9","key":"10.1016\/j.lfs.2021.119289_bb0160","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0001295","article-title":"In silico analysis of six known leishmania major antigens and in vitro evaluation of specific epitopes eliciting HLA-A2 restricted CD8 T cell response","volume":"5","author":"Seyed","year":"2011","journal-title":"PLoS Negl. Trop. Dis."},{"issue":"5","key":"10.1016\/j.lfs.2021.119289_bb0165","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1586\/erv.09.26","article-title":"How to design effective vaccines: lessons from an old success story","volume":"8","author":"Ahmed","year":"2009","journal-title":"Expert Rev Vaccines"},{"issue":"1","key":"10.1016\/j.lfs.2021.119289_bb0170","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1093\/bmb\/62.1.201","article-title":"Vaccine programmes and policies","volume":"62","author":"Miller","year":"2002","journal-title":"Br. Med. Bull."},{"issue":"1","key":"10.1016\/j.lfs.2021.119289_bb0175","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1080\/21645515.2015.1093263","article-title":"Primary vaccine failure to routine vaccines: why and what to do?","volume":"12","author":"Wiedermann","year":"2016","journal-title":"Human Vaccines & Immunotherapeutics"},{"issue":"e01023\u201318","key":"10.1016\/j.lfs.2021.119289_bb0180","article-title":"Engineered dengue virus domain III proteins elicit cross- neutralizing antibody responses in mice","volume":"92","author":"Frei","year":"2018","journal-title":"J. Virol."},{"key":"10.1016\/j.lfs.2021.119289_bb0185","doi-asserted-by":"crossref","DOI":"10.1093\/nsr\/nwaa036","article-title":"On the origin and continuing evolution of SARS-CoV-2","author":"Tang","year":"2020","journal-title":"Natl. Sci. Rev."},{"key":"10.1016\/j.lfs.2021.119289_bb0190","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/v12050526","article-title":"SARS-CoV-2\/COVID-19: viral genomics, epidemiology, vaccines, and therapeutic interventions","volume":"12","author":"Uddin","year":"2020","journal-title":"Viruses"},{"key":"10.1016\/j.lfs.2021.119289_bb0195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/vaccines8020153","article-title":"Progress and prospects on vaccine development against SARS-CoV-2","volume":"8","author":"Zhang","year":"2020","journal-title":"Vaccines"},{"key":"10.1016\/j.lfs.2021.119289_bb0200","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.drudis.2019.12.003","article-title":"Comparison of DNA and mRNA vaccines against cancer","volume":"25","author":"Jahanafrooz","year":"2020","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.lfs.2021.119289_bb0205","doi-asserted-by":"crossref","first-page":"594","DOI":"10.3389\/fimmu.2019.00594","article-title":"Advances in mRNA vaccines for infectious diseases","volume":"10","author":"Zhang","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.lfs.2021.119289_bb0210","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1002\/jgm.960","article-title":"Adenoviral vector platform for transduction of constitutive and regulated tricistronic or triple-transcript transgene expression in mammalian cells and microtissues","volume":"8","author":"Gonzalez-Nicolini","year":"2006","journal-title":"J. Gene Med."},{"key":"10.1016\/j.lfs.2021.119289_bb0215","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0108169","article-title":"Characterization of chikungunya virus-like particles","volume":"9","author":"Noranate","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.lfs.2021.119289_bb0220","doi-asserted-by":"crossref","first-page":"4321","DOI":"10.1007\/s00253-014-5639-1","article-title":"Virus-like particles in picornavirus vaccine development","volume":"98","author":"Dong","year":"2014","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"10.1016\/j.lfs.2021.119289_bb0225","doi-asserted-by":"crossref","first-page":"411","DOI":"10.3201\/eid1103.040906","article-title":"Longitudinally profiling neutralizing antibody response to SARS coronavirus with pseudotypes","volume":"11","author":"Temperton","year":"2005","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.lfs.2021.119289_bb0230","first-page":"406","article-title":"Mechanism of immunopotentiation and safety of aluminum adjuvants","volume":"3","author":"Hogenesch","year":"2012","journal-title":"Front. Immunol."},{"key":"10.1016\/j.lfs.2021.119289_bb0235","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3947\/ic.2013.45.2.159","article-title":"Fluad(R)-MF59(R)-adjuvanted influenza vaccine in older adults","volume":"45","author":"Tsai","year":"2013","journal-title":"Infect. Chemother."},{"key":"10.1016\/j.lfs.2021.119289_bb0240","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1080\/14760584.2016.1213632","article-title":"Adjuvant system AS01: helping to overcome the challenges of modern vaccines","volume":"16","author":"Didierlaurent","year":"2017","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.lfs.2021.119289_bb0245","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1007\/s40264-015-0350-4","article-title":"Comparative safety of vaccine adjuvants: a summary of current evidence and future needs","volume":"38","author":"Petrovsky","year":"2015","journal-title":"Drug Saf."},{"key":"10.1016\/j.lfs.2021.119289_bb0250","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/d41586-020-00751-9","article-title":"Don't rush to deploy COVID-19 vaccines and drugs without sufficient safety guarantees","volume":"579","author":"Jiang","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.lfs.2021.119289_bb0255","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nrmicro2090","article-title":"The spike protein of SARS-CoV\u2013a target for vaccine and therapeutic development","volume":"7","author":"Du","year":"2009","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.lfs.2021.119289_bb0260","first-page":"4","article-title":"Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection","author":"Liu","year":"2019","journal-title":"JCI Insight"},{"issue":"3","key":"10.1016\/j.lfs.2021.119289_bb0265","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.dsx.2020.03.011","article-title":"Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries","volume":"14","author":"Singh","year":"2020","journal-title":"Diabetes Metab Syndr"},{"key":"10.1016\/j.lfs.2021.119289_bb0270","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2020.00184","article-title":"SARS-CoV-2 and the use of chloroquine as an antiviral treatment","author":"Rebeaud","year":"2020","journal-title":"Front. Med."},{"key":"10.1016\/j.lfs.2021.119289_bb0275","first-page":"35","article-title":"Browning. Pharmacology of Chloroquine and Hydroxychloroquine","author":"David","year":"2014","journal-title":"Hydroxychloroquine and Chloroquine Retinopathy"},{"key":"10.1016\/j.lfs.2021.119289_bb0280","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(20)31022-9","article-title":"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial","author":"Wang","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.lfs.2021.119289_bb0285","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2007016","article-title":"Compassionate use of remdesivir for patients with severe COVID-19","author":"Grein","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lfs.2021.119289_bb0290","article-title":"Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency","author":"Gordon","year":"2020","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.lfs.2021.119289_bb0295","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(20)31022-9","article-title":"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial","author":"Wang","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.lfs.2021.119289_bb0300","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2001282","article-title":"A trial of lopinavir\u2013ritonavir in adults hospitalized with severe COVID-19","author":"Cao","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lfs.2021.119289_bb0305","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.2217\/fvl.13.98","article-title":"Synergistic combinations of favipiravir and oseltamivir against wild-type pandemic and oseltamivir-resistant influenza A virus infections in mice","volume":"8","author":"Smee","year":"2013","journal-title":"Future Virol"},{"key":"10.1016\/j.lfs.2021.119289_bb0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.eng.2020.03.007","article-title":"Experimental treatment with favipiravir for COVID-19: an open-label control study","author":"Cai","year":"2020","journal-title":"Engineering"},{"issue":"1","key":"10.1016\/j.lfs.2021.119289_bb0315","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1021\/acs.jmedchem.6b01465","article-title":"Rational design of novel highly potent and selective Phosphatidylinositol 4-Kinase III\u03b2 (PI4KB) inhibitors as broad-spectrum antiviral agents and tools for chemical biology","volume":"60","author":"Mejdrov\u00e1","year":"2017","journal-title":"J. Med. Chem."},{"issue":"9","key":"10.1016\/j.lfs.2021.119289_bb0320","doi-asserted-by":"crossref","DOI":"10.3390\/v10090453","article-title":"Host-directed antivirals: a realistic alternative to fight Zika virus","volume":"10","author":"Saiz","year":"2018","journal-title":"Viruses"},{"issue":"5","key":"10.1016\/j.lfs.2021.119289_bb0325","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1002\/jmv.25709","article-title":"Overlapping and discrete aspects of the pathology and pathogenesis of the emerging human pathogenic coronaviruses SARSCoV, MERS-CoV, and 2019- nCoV","volume":"92","author":"Liu","year":"2020","journal-title":"J. Med. Virol."},{"issue":"19","key":"10.1016\/j.lfs.2021.119289_bb0330","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1093\/eurheartj\/ehaa235","article-title":"SARS-CoV2: should inhibitors of the renin-angiotensin system be withdrawn in patients with COVID-19?","volume":"41","author":"Kuster","year":"2020","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.lfs.2021.119289_bb0335","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1161\/CIRCRESAHA.120.317134","article-title":"Association of inpatient use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19","volume":"126","author":"Zhang","year":"2020","journal-title":"Circ. Res."},{"issue":"7798","key":"10.1016\/j.lfs.2021.119289_bb0340","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.lfs.2021.119289_bb0345","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1042\/BJ20040634","article-title":"Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism","volume":"383","author":"Rice","year":"2004","journal-title":"Biochem. J."},{"key":"10.1016\/j.lfs.2021.119289_bb0350","first-page":"E1","article-title":"COVID-19 and angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: what is the evidence?","author":"Patel","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.lfs.2021.119289_bb0355","doi-asserted-by":"crossref","DOI":"10.1007\/s11886-020-01291-4","article-title":"Outcomes in patients with COVID-19 infection taking ACEI\/ARB","volume":"22","author":"Rico-Mesa","year":"2020","journal-title":"Curr. Cardiol. Rep."},{"key":"10.1016\/j.lfs.2021.119289_bb0360","doi-asserted-by":"crossref","DOI":"10.1038\/s41423-020-0374-2","article-title":"Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein","author":"Xia","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.lfs.2021.119289_bb0365","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/s41422-020-0290-0","article-title":"Virus against virus: A potential treatment for 2019-nCov (SARS-CoV-2) and other RNA viruses","volume":"30","author":"Nguyen","year":"2020","journal-title":"Cell Res."},{"issue":"5","key":"10.1016\/j.lfs.2021.119289_bb0370","first-page":"1","article-title":"The coronavirus macrodomain is required to prevent PARP-mediated inhibition of virus replication and enhancement of IFN expression","author":"Grunewald","year":"2019","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.lfs.2021.119289_bb0375","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/cr.2008.15","article-title":"SARS coronavirus entry into host cells through a novel clathrin- and caveolae-independent endocytic pathway","volume":"18","author":"Wang","year":"2008","journal-title":"Cell Res."},{"key":"10.1016\/j.lfs.2021.119289_bb0380","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.addr.2019.05.001","article-title":"The significance of artificial intelligence in drug delivery system design","volume":"151\u2013152","author":"Hassanzadeh","year":"2019","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.lfs.2021.119289_bb0385","doi-asserted-by":"crossref","first-page":"4387","DOI":"10.1128\/JVI.02705-14","article-title":"AP-2-associated protein kinase 1 and cyclin G-associated kinase regulate hepatitis C virus entry and are potential drug targets","volume":"89","author":"Neveu","year":"2015","journal-title":"J. Virol."},{"key":"10.1016\/j.lfs.2021.119289_bb0390","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1016\/S0140-6736(20)30304-4","article-title":"Baricitinib as potential treatment for 2019-nCoV acute respiratory disease","volume":"395","author":"Richardson","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.lfs.2021.119289_bb0395","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.bbrc.2011.09.119","article-title":"Role of the p21-activated kinases (PAKs) in influenza A virus replication","volume":"414","author":"Pascua","year":"2011","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.lfs.2021.119289_bb0400","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1586\/eri.12.104","article-title":"Development of novel entry inhibitors targeting emerging viruses","volume":"10","author":"Zhou","year":"2012","journal-title":"Expert Rev. Anti-Infect. Ther."},{"key":"10.1016\/j.lfs.2021.119289_bb0405","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.ejmech.2016.11.038","article-title":"1,2,3-Triazolyl ester of ketorolac: A \u201cclick chemistry\u201d-based highly potent PAK1-blocking cancer-killer","volume":"126","author":"Nguyen","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.lfs.2021.119289_bb0410","doi-asserted-by":"crossref","first-page":"9334","DOI":"10.1021\/acs.jmedchem.5b01329","article-title":"Phosphonooxymethyl prodrug of triptolide: synthesis, physicochemical characterization, and efficacy in human colon adenocarcinoma and ovarian cancer xenografts","volume":"58","author":"Patil","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.lfs.2021.119289_bb0415","doi-asserted-by":"crossref","first-page":"110","DOI":"10.5582\/ddt.2017.01011","article-title":"A from sea cucumber and nymphaeols from Okinawa propolis: natural anti-cancer agents that selectively inhibit PAK1 in vitro","volume":"11","author":"Nguyen","year":"2017","journal-title":"Drug Discov. Ther."},{"key":"10.1016\/j.lfs.2021.119289_bb0420","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0140-6736(20)30317-2","article-title":"Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury","volume":"395","author":"Russell","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.lfs.2021.119289_bb0425","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41392-020-0127-9","article-title":"Potential benefits of precise corticosteroids therapy for severe 2019-nCoV pneumonia","volume":"5","author":"Zhou","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.lfs.2021.119289_bb0430","doi-asserted-by":"crossref","DOI":"10.1007\/s12250-020-00207-4","article-title":"Understanding SARS-CoV-2-mediated inflammatory responses: from mechanisms to potential therapeutic tools","author":"Fu","year":"2020","journal-title":"Virol. Sin."},{"key":"10.1016\/j.lfs.2021.119289_bb0435","article-title":"Aberrant pathogenic GM-CSF+ T cells and inflammatory CD14+CD16+ monocytes in severe pulmonary syndrome patients of a new coronavirus","author":"Zhou","year":"2020","journal-title":"BioRxiv"},{"key":"10.1016\/j.lfs.2021.119289_bb0440","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(20)30141-9","article-title":"Convalescent plasma as a potential therapy for COVID-19","author":"Chen","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.lfs.2021.119289_bb0445","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.tracli.2015.12.003","article-title":"Plasma therapy against infectious pathogens, as of yesterday, today and tomorrow","volume":"23","author":"Garraud","year":"2016","journal-title":"Transfus. Clin. Biol."},{"issue":"278","key":"10.1016\/j.lfs.2021.119289_bb0450","first-page":"1","article-title":"Characterization of novel monoclonal antibodies against MERS-coronavirus spike protein","volume":"197863","author":"Gooa","year":"2020","journal-title":"Virus Res."},{"key":"10.1016\/j.lfs.2021.119289_bb0455","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-020-2196-x","article-title":"Virological assessment of hospitalized patients with COVID-2019","author":"W\u00f6lfel","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.lfs.2021.119289_bb0460","article-title":"The immunobiology of humanized anti-IL6 receptor antibody: from basic research to breakthrough medicine","volume":"3","author":"Ohsug","year":"2020","journal-title":"J Translational Autoimmunity"},{"key":"10.1016\/j.lfs.2021.119289_bb0465","first-page":"1","article-title":"Tocilizumab: from the rheumatology practice to the fight against COVID-19, a virus infection with multiple faces","volume":"1","author":"Gonz\u00e1lez-Gay","year":"2020","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.lfs.2021.119289_bb0470","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1038\/nprot.2016.123","article-title":"A decade of progress in tissue engineering","volume":"11","author":"Khademhosseini","year":"2016","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.lfs.2021.119289_bb0475","doi-asserted-by":"crossref","first-page":"19","DOI":"10.14748\/bmr.v23.26","article-title":"Tissue engineering and growth factors: updated evidence","volume":"23","author":"Hassanzadeh","year":"2012","journal-title":"Biomed Rev"},{"key":"10.1016\/j.lfs.2021.119289_bb0480","first-page":"468","article-title":"Role of tissue engineering in COVID-19 and future viral outbreaks","volume":"26","author":"Tatara","year":"2020"},{"key":"10.1016\/j.lfs.2021.119289_bb0485","first-page":"246","article-title":"In vitro models to study human lung development, disease and homeostasis","volume":"32","author":"Miller","year":"2017","journal-title":"Physiology (Bethesda)"},{"key":"10.1016\/j.lfs.2021.119289_bb0490","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jconrel.2018.04.024","article-title":"Tissue engineering: still facing a long way ahead","volume":"279","author":"Hassanzadeh","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.lfs.2021.119289_bb0495","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/cmdc.201300555","article-title":"Toward drug repurposing in epigenetics: olsalazine as a hypomethylating compound active in a cellular context","volume":"9","author":"M\u00e9ndez-Lucio","year":"2014","journal-title":"ChemMedChem"},{"key":"10.1016\/j.lfs.2021.119289_bb0500","doi-asserted-by":"crossref","DOI":"10.5582\/bst.2020.01020","article-title":"Drug treatment options for the 2019-new coronavirus (2019-nCoV)","author":"Lu","year":"2020","journal-title":"Biosci Trends"},{"key":"10.1016\/j.lfs.2021.119289_bb0505","doi-asserted-by":"crossref","DOI":"10.5582\/bst.2020.01030","article-title":"Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment","author":"Wang","year":"2020","journal-title":"Biosci Trends"},{"issue":"1","key":"10.1016\/j.lfs.2021.119289_bb0510","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/msb.2012.66","article-title":"Genome-scale engineering for systems and synthetic biology","volume":"9","author":"Esvelt","year":"2013","journal-title":"Mol. Syst. Biol."},{"issue":"1","key":"10.1016\/j.lfs.2021.119289_bb0515","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nmeth.1852","volume":"9","author":"Method of the Year 2011","year":"2012","journal-title":"Nat. Methods"},{"year":"2015","series-title":"Breakthrough of the Year: CRISPR Makes the Cut","author":"Science News Staff","key":"10.1016\/j.lfs.2021.119289_bb0520"},{"issue":"6","key":"10.1016\/j.lfs.2021.119289_bb0525","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/0168-9525(96)10019-6","article-title":"Genetic manipulation of genomes with rare-cutting endonucleases","volume":"12","author":"Jasin","year":"1996","journal-title":"Trends Genet."},{"issue":"1","key":"10.1016\/j.lfs.2021.119289_bb0530","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/nmeth.1811","article-title":"Gene editing: not just for translation anymore","volume":"9","author":"McMahon","year":"2011","journal-title":"Nat. Methods"},{"key":"10.1016\/j.lfs.2021.119289_bb0535","first-page":"1","article-title":"Tools for translation: non-viral materials for therapeutic mRNA delivery","volume":"2","author":"Hajj","year":"2017","journal-title":"Nat Rev"},{"issue":"9","key":"10.1016\/j.lfs.2021.119289_bb0540","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1038\/nbt.3659","article-title":"Applications of CRISPR technologies in research and beyond","volume":"34","author":"Barrangou","year":"2016","journal-title":"Nat. Biotechnol."},{"issue":"3","key":"10.1016\/j.lfs.2021.119289_bb0545","doi-asserted-by":"crossref","first-page":"136","DOI":"10.14802\/jmd.16029","article-title":"Applications of CRISPR\/Cas9 for gene editing in hereditary movement disorders","volume":"9","author":"Moon","year":"2016","journal-title":"JMovement Disorders"},{"issue":"6","key":"10.1016\/j.lfs.2021.119289_bb0550","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.cell.2014.05.010","article-title":"Development and applications of CRISPR-Cas9 for genome engineering","volume":"157","author":"Hsu","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.lfs.2021.119289_bb0555","doi-asserted-by":"crossref","DOI":"10.1126\/science.1258096","article-title":"The new frontier of genome engineering with CRISPR-Cas9","volume":"346","author":"Doudna","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.lfs.2021.119289_bb0560","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1126\/science.1231143","article-title":"Multiplex genome engineering using CRISPR\/Cas systems","volume":"339","author":"Cong","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.lfs.2021.119289_bb0565","doi-asserted-by":"crossref","first-page":"6164","DOI":"10.1073\/pnas.1422340112","article-title":"Cas9-mediated targeting of viral RNA in eukaryotic cells","volume":"112","author":"Price","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.lfs.2021.119289_bb0570","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1126\/science.1179555","article-title":"CRISPR\/Cas, the immune system of bacteria and archaea","volume":"327","author":"Horvath","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.lfs.2021.119289_bb0575","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/nbt.2647","article-title":"DNA targeting specificity of RNA-guided Cas9 nucleases","volume":"31","author":"Hsu","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.lfs.2021.119289_bb0580","doi-asserted-by":"crossref","first-page":"4336","DOI":"10.1093\/nar\/gkt135","article-title":"Genome engineering in Saccharomyces cerevisiae using CRISPR-Cas systems","volume":"41","author":"DiCarlo","year":"2013","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.lfs.2021.119289_bb0585","doi-asserted-by":"crossref","first-page":"4220","DOI":"10.1016\/j.vaccine.2013.03.042","article-title":"Reflections on the early development of poxvirus vectors","volume":"31","author":"Moss","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.lfs.2021.119289_bb0590","doi-asserted-by":"crossref","first-page":"5176","DOI":"10.1128\/JVI.00339-15","article-title":"Efficiently editing the Vaccinia virus genome by using the CRISPR-Cas9 system","volume":"89","author":"Yuan","year":"2015","journal-title":"J. Virol."},{"issue":"6366","key":"10.1016\/j.lfs.2021.119289_bb0595","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1126\/science.aaq0180","article-title":"RNA editing with CRISPR-Cas13","volume":"358","author":"Cox","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.lfs.2021.119289_bb0600","doi-asserted-by":"crossref","first-page":"5573","DOI":"10.1126\/science.aaf5573","article-title":"C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector","volume":"353","author":"Abudayyeh","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.lfs.2021.119289_bb0605","doi-asserted-by":"crossref","first-page":"10864","DOI":"10.1128\/JVI.00238-08","article-title":"Double-stranded RNA adenosine deaminases enhance expression of human immunodeficiency virus type 1 proteins","volume":"82","author":"Phuphuakrat","year":"2008","journal-title":"J. Virol."},{"key":"10.1016\/j.lfs.2021.119289_bb0610","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abb5813","article-title":"Evidence for host-dependent RNA editing in the transcriptome of SARS-CoV-2","author":"Di Giorgio","year":"2020","journal-title":"Sci. Adv."},{"issue":"3","key":"10.1016\/j.lfs.2021.119289_bb0615","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1005471","article-title":"The preferred nucleotide contexts of the AID\/APOBEC cytidine deaminases have differential effects when mutating retrotransposon and virus sequences compared to host genes","volume":"13","author":"Chen","year":"2017","journal-title":"PLoS Comput. Biol."},{"key":"10.1016\/j.lfs.2021.119289_bb0620","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1111\/nph.14702","article-title":"Towards CRISPR\/Cas crops \u2013 bringing together genomics and genome editing","volume":"216","author":"Scheben","year":"2017","journal-title":"New Phytol."},{"key":"10.1016\/j.lfs.2021.119289_bb0625","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/nature12048","article-title":"A CRISPR\/Cas system mediates bacterial innate immune evasion and virulence","volume":"497","author":"Sampson","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.lfs.2021.119289_bb0630","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/nature24049","article-title":"RNA targeting with CRISPR\u2013Cas13","volume":"550","author":"Abudayyeh","year":"2017","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.lfs.2021.119289_bb0635","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1111\/pbi.12881","article-title":"Establishing RNA virus resistance in plants by harnessing CRISPR immune system","volume":"16","author":"Zhang","year":"2018","journal-title":"Plant Biotechnol. J."},{"key":"10.1016\/j.lfs.2021.119289_bb0640","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1126\/science.1225829","article-title":"A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity","volume":"337","author":"Jinek","year":"2012","journal-title":"Sci. N. Y. NY"},{"key":"10.1016\/j.lfs.2021.119289_bb0645","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-018-07845-z","article-title":"Genome editing in primary cells and in vivo using viral-derived Nanoblades loaded with Cas9-sgRNA ribonucleoproteins","volume":"10","author":"Mangeot","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.lfs.2021.119289_bb0650","first-page":"133","article-title":"Coronavirus reverse genetics by targeted RNA recombination","volume":"287","author":"Masters","year":"2005","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/j.lfs.2021.119289_bb0655","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/978-1-59745-181-9_17","article-title":"Manipulation of the coronavirus genome using targeted RNA recombination with interspecies chimeric coronaviruses","volume":"454","author":"de Haan","year":"2008","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.lfs.2021.119289_bb0660","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.ppat.1004090","article-title":"High-efficiency targeted editing of large viral genomes by RNA-guided nucleases","volume":"10","author":"Bi","year":"2014","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.lfs.2021.119289_bb0665","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/mt.2015.164","article-title":"Engineered viruses as genome editing devices","volume":"24","author":"Chen","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.lfs.2021.119289_bb0670","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/mt.2009.319","article-title":"Recent advances in lentiviral vector development and applications","volume":"18","author":"M\u00e1trai","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.lfs.2021.119289_bb0675","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/nrg2985","article-title":"Ex vivo gene transfer and correction for cell-based therapies","volume":"12","author":"Naldini","year":"2011","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.lfs.2021.119289_bb0680","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.stem.2014.06.016","article-title":"Targeted gene correction minimally impacts whole-genome mutational load in human-disease-specific induced pluripotent stem cell clones","volume":"15","author":"Suzuki","year":"2014","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.lfs.2021.119289_bb0685","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1089\/hgtb.2012.243","article-title":"Pre-existing antiadeno-associated virus antibodies as a challenge in AAV gene therapy","volume":"24","author":"Louis Jeune","year":"2013","journal-title":"Hum Gene Ther Methods"},{"key":"10.1016\/j.lfs.2021.119289_bb0690","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.1093\/nar\/gku936","article-title":"Easy quantitative assessment of genome editing by sequence trace decomposition","volume":"42","author":"Brinkman","year":"2014","journal-title":"Nucleic Acids Res."},{"issue":"22","key":"10.1016\/j.lfs.2021.119289_bb0695","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1038\/gt.2008.145","article-title":"Progress and prospects: zinc-finger nucleases as gene therapy agents","volume":"15","author":"Carroll","year":"2008","journal-title":"Gene Ther."},{"key":"10.1016\/j.lfs.2021.119289_bb0700","first-page":"73","article-title":"Efficient delivery of genome-editing proteins in vitro and in vivo","volume":"33","author":"Zuris","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.lfs.2021.119289_bb0705","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2174\/1389201053167248","article-title":"Nanotechnology on duty in medical applications","volume":"6","author":"Kubik","year":"2005","journal-title":"Curr. Pharm. Biotechnol."},{"key":"10.1016\/j.lfs.2021.119289_bb0710","doi-asserted-by":"crossref","first-page":"25","DOI":"10.14748\/bmr.v25.1043","article-title":"Nanopharmaceuticals: innovative theranostics for the neurological disorders","volume":"25","author":"Hassanzadeh","year":"2014","journal-title":"Biomed Rev"},{"issue":"3","key":"10.1016\/j.lfs.2021.119289_bb0715","first-page":"105","article-title":"New perspectives in biosensor technology","volume":"3","author":"Hassanzadeh","year":"2010","journal-title":"Gastroenterology and Hepatology From Bed to Bench"},{"key":"10.1016\/j.lfs.2021.119289_bb0720","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.3181\/0904-MR-134","article-title":"Engineering nanomaterial surfaces for biomedical applications","volume":"234","author":"Wang","year":"2009","journal-title":"Exp. Biol. Med."},{"issue":"4","key":"10.1016\/j.lfs.2021.119289_bb0725","first-page":"105","article-title":"The role of nanotechnology in the treatment of viral infections","volume":"4","author":"Singh","year":"2017","journal-title":"Ther Adv in Infect Dis"},{"key":"10.1016\/j.lfs.2021.119289_bb0730","first-page":"1","article-title":"Applying nanoparticles in the treatment of viral infections and toxicological considerations","volume":"5","author":"Fasili","year":"2019","journal-title":"Pharmaceutical and Biomedical Research"},{"key":"10.1016\/j.lfs.2021.119289_bb0735","doi-asserted-by":"crossref","first-page":"430","DOI":"10.3390\/ijerph13040430","article-title":"Antiviral activity of graphene\u2013silver nanocomposites against non-enveloped and enveloped viruses","volume":"13","author":"Chen","year":"2016","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"10.1016\/j.lfs.2021.119289_bb0740","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1477-3155-3-6","article-title":"Interaction of silver nanoparticles with HIV-1","volume":"3","author":"Elechiguerra","year":"2005","journal-title":"J. Nanobiotechnology"},{"key":"10.1016\/j.lfs.2021.119289_bb0745","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.nano.2019.03.004","article-title":"Nano-based approach to combat emerging viral (NIPAH virus) infection","volume":"18","author":"Kerry","year":"2019","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"10.1016\/j.lfs.2021.119289_bb0750","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1039\/c3nr33492a","article-title":"Multiplexed colorimetric detection of Kaposi's sarcoma associated herpesvirus and Bartonella DNA using gold and silver nanoparticles","volume":"5","author":"Mancuso","year":"2013","journal-title":"Nanoscale"},{"key":"10.1016\/j.lfs.2021.119289_bb0755","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1021\/bc900215b","article-title":"Inhibition of herpes simplex virus type 1 infection by silver nanoparticles capped with mercaptoethane sulfonate","volume":"20","author":"Baram-Pinto","year":"2009","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.lfs.2021.119289_bb0760","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0104113","article-title":"Tannic acid modified silver nanoparticles show antiviral activity in herpes simplex virus type 2 infection","volume":"9","author":"Orlowski","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.lfs.2021.119289_bb0765","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.7150\/thno.23856","article-title":"Applications of gold nanoparticles in virus detection","volume":"8","author":"Draz","year":"2018","journal-title":"Theranostics"},{"key":"10.1016\/j.lfs.2021.119289_bb0770","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.mset.2019.10.002","article-title":"Colorimetric biosensors for point-of-care virus detections","volume":"3","author":"Ting Zhao","year":"2020","journal-title":"Materials Science for Energy Technologies"},{"key":"10.1016\/j.lfs.2021.119289_bb0775","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.clinbiochem.2010.07.001","article-title":"Direct detection of unamplified hepatitis C virus RNA using unmodified gold nanoparticles","volume":"43","author":"Shawky","year":"2010","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.lfs.2021.119289_bb0780","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.bios.2012.02.001","article-title":"A highly selective and colorimetric assay of lysine by molecular-driven gold nanorods assembly","volume":"34","author":"Wang","year":"2012","journal-title":"Biosens. Bioelectron."},{"key":"10.1016\/j.lfs.2021.119289_bb0785","first-page":"167","article-title":"Carbon nanotubes prolong the regulatory action of nerve growth factor on the endocannabinoid signaling","volume":"19","author":"Hassanzadeh","year":"2015","journal-title":"Physiol Pharmacol"},{"key":"10.1016\/j.lfs.2021.119289_bb0790","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.lfs.2016.11.015","article-title":"Application of carbon nanotubes as the carriers of the cannabinoid, 2-arachidonoylglycerol: towards a novel treatment strategy in colitis","volume":"179","author":"Hassanzadeh","year":"2017","journal-title":"Life Sci."},{"key":"10.1016\/j.lfs.2021.119289_bb0795","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.lfs.2016.11.029","article-title":"Nerve growth factor-carbon nanotube complex exerts prolonged protective effects in an in vitro model of ischemic stroke","volume":"179","author":"Hassanzadeh","year":"2017","journal-title":"Life Sci."},{"key":"10.1016\/j.lfs.2021.119289_bb0800","doi-asserted-by":"crossref","first-page":"41","DOI":"10.14748\/bmr.v27.2105","article-title":"Application of carbon nanotubes for controlled release of growth factors or endocannabinoids: a breakthrough in biomedicine","volume":"27","author":"Hassanzadeh","year":"2017","journal-title":"Biomedical Reviews"},{"key":"10.1016\/j.lfs.2021.119289_bb0805","first-page":"38","article-title":"Carbon nanotubes provide longer lasting gastroprotective effects for anandamide in stressinduced gastric ulcer in rat","volume":"22","author":"Hassanzadeh","year":"2018","journal-title":"Physiol Pharmacol"},{"key":"10.1016\/j.lfs.2021.119289_bb0810","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S1452-3981(23)15193-5","article-title":"Direct electron transfer of polyphenol oxidase on carbon nanotube surfaces: application in biosensing","volume":"4","author":"Mohammadi","year":"2009","journal-title":"Int. J. Electrochem. Sci."},{"key":"10.1016\/j.lfs.2021.119289_bb0815","doi-asserted-by":"crossref","DOI":"10.1016\/j.aquaculture.2019.734377","article-title":"Anti-betanodavirus activity of isoprinosine and improved efficacy using carbon nanotubes based drug delivery system","volume":"512","author":"Zhu","year":"2019","journal-title":"Aquaculture"},{"key":"10.1016\/j.lfs.2021.119289_bb0820","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.antiviral.2015.03.006","article-title":"Carbon nanotube-based nanocarrier loaded with ribavirin against grass carp reovirus","volume":"118","author":"Zhu","year":"2015","journal-title":"Antivir. Res."},{"key":"10.1016\/j.lfs.2021.119289_bb0825","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1038\/s41565-019-0382-5","article-title":"High aspect ratio nanomaterials enable delivery of functional genetic material without DNA integration in mature plants","volume":"14","author":"Demirer","year":"2019","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.lfs.2021.119289_bb0830","doi-asserted-by":"crossref","first-page":"22545","DOI":"10.1039\/c4ra02277g","article-title":"Detection of Epstein- Barr virus infection in cancer by using highly specific nanoprobe based on dBSA capped CdTe quantum dots","volume":"4","author":"Li","year":"2014","journal-title":"RSC Adv."},{"key":"10.1016\/j.lfs.2021.119289_bb0835","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1021\/ac203102u","article-title":"Robust and highly sensitive fluorescence approach for point-of-care virus detection based on immunomagnetic separation","volume":"84","author":"Zhao","year":"2012","journal-title":"Anal. Chem."},{"key":"10.1016\/j.lfs.2021.119289_bb0840","doi-asserted-by":"crossref","first-page":"3333","DOI":"10.1021\/acs.biomac.9b00783","article-title":"Nonviral nanoparticles for CRISPR-based genome editing: is it just a simple adaption of what have been developed for nucleic acid delivery?","volume":"20","author":"Qiu","year":"2019","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.lfs.2021.119289_bb0845","doi-asserted-by":"crossref","first-page":"E9944","DOI":"10.1073\/pnas.1811276115","article-title":"High-throughput in vivo screen of functional mRNA delivery identifies nanoparticles for endothelial cell gene editing","volume":"115","author":"Sago","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.lfs.2021.119289_bb0850","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1073\/pnas.1620874114","article-title":"Barcoded nanoparticles for high throughput in vivo discovery of targeted therapeutics","volume":"114","author":"Wang","year":"2017","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.lfs.2021.119289_bb0855","doi-asserted-by":"crossref","DOI":"10.1186\/s40199-017-0191-z","article-title":"Application of nanostructured lipid carriers: the prolonged protective effects for sesamol in in vitro and in vivo models of ischemic stroke via activation of PI3K signalling pathway","volume":"25","author":"Hassanzadeh","year":"2017","journal-title":"DARU Journal of Pharmaceutical Sciences"},{"key":"10.1016\/j.lfs.2021.119289_bb0860","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.lfs.2017.11.046","article-title":"Ferulic acid-loaded nanostructured lipid carriers: a promising nanoformulation against the ischemic neural injuries","volume":"193","author":"Hassanzadeh","year":"2018","journal-title":"Life Sci."},{"key":"10.1016\/j.lfs.2021.119289_bb0865","first-page":"331","article-title":"Aerosol delivery of ferulic acid-loaded nanostructured lipid carriers: a promising treatment approach against the respiratory disorders","volume":"21","author":"Hassanzadeh","year":"2017","journal-title":"Physiol Pharmacol"},{"key":"10.1016\/j.lfs.2021.119289_bb0870","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.jconrel.2019.05.032","article-title":"Therapeutic mRNA delivery to leukocytes","volume":"305","author":"Granot-Matok","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.lfs.2021.119289_bb0875","doi-asserted-by":"crossref","first-page":"E9944","DOI":"10.1073\/pnas.1811276115","article-title":"High-throughput in vivo screen of functional mRNA delivery identifies nanoparticles for endothelial cell gene editing","volume":"115","author":"Sago","year":"2018","journal-title":"Proc. Natl. Acad. Sci. Unit. States Am"},{"key":"10.1016\/j.lfs.2021.119289_bb0880","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s12195-018-0536-9","article-title":"Lipid polymer hybrid nanomaterials for mRNA delivery","volume":"11","author":"Zhao","year":"2018","journal-title":"Cell. Mol. Bioeng"},{"key":"10.1016\/j.lfs.2021.119289_bb0885","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.jconrel.2015.08.007","article-title":"Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes","volume":"217","author":"Pardi","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.lfs.2021.119289_bb0890","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1038\/mt.2015.103","article-title":"Sequence-engineered mRNA without chemical nucleoside modifications enables an effective protein therapy in large animals","volume":"23","author":"Thess","year":"2015","journal-title":"Mol. Ther."},{"key":"10.1016\/j.lfs.2021.119289_bb0895","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms14630","article-title":"Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge","volume":"8","author":"Pardi","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.lfs.2021.119289_bb0900","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.ymthe.2019.03.003","article-title":"Non-viral delivery of zinc finger nuclease mrna enables highly efficient in vivo genome editing of multiple therapeutic gene targets","volume":"27","author":"Conway","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.lfs.2021.119289_bb0905","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.bioactmat.2020.03.001","article-title":"Long-term storage of lipid-like nanoparticles for mRNA delivery","volume":"5","author":"Zhaoa","year":"2020","journal-title":"Bioactive Materials"},{"key":"10.1016\/j.lfs.2021.119289_bb0910","doi-asserted-by":"crossref","first-page":"8698","DOI":"10.1021\/acs.jpcb.5b02891","article-title":"Microfluidic mixing: a general method for encapsulating macromolecules in lipid nanoparticle systems","volume":"119","author":"Leung","year":"2015","journal-title":"J. Phys. Chem. B"},{"key":"10.1016\/j.lfs.2021.119289_bb0915","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2012.28","article-title":"Microfluidic synthesis of highly potent limit-size lipid nanoparticles for in vivo delivery of siRNA","volume":"1","author":"Belliveau","year":"2012","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.lfs.2021.119289_bb0920","doi-asserted-by":"crossref","first-page":"6948","DOI":"10.1021\/ja301621z","article-title":"Rapid discovery of potent siRNA-containing lipid nanoparticles enabled by controlled microfluidic formulation","volume":"134","author":"Chen","year":"2012","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.lfs.2021.119289_bb0925","doi-asserted-by":"crossref","first-page":"9023","DOI":"10.1039\/C9NR02004G","article-title":"Fusion-dependent formation of lipid nanoparticles containing macromolecular payloads","volume":"11","author":"Kulkarni","year":"2019","journal-title":"Nanoscale"},{"issue":"6","key":"10.1016\/j.lfs.2021.119289_bb0930","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1517\/14712590902989970","article-title":"Prospects of RNAi and microRNA-based therapies for hepatitis C","volume":"9","author":"Pan","year":"2009","journal-title":"Expert. Opin. Biol. Ther."},{"issue":"6","key":"10.1016\/j.lfs.2021.119289_bb0935","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/sj.cr.7290248","article-title":"RNAi, a new therapeutic strategy against viral infection","volume":"14","author":"Tan","year":"2004","journal-title":"Cell Res."},{"key":"10.1016\/j.lfs.2021.119289_bb0940","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/nrd2310","volume":"6","author":"De Fougerolles","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.lfs.2021.119289_bb0945","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1517\/13543784.15.2.89","article-title":"Antiviral applications of RNAi for coronavirus","volume":"15","author":"Wu","year":"2006","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.lfs.2021.119289_bb0950","first-page":"225","article-title":"siRNA-mediated antitumorgenesis for drug target validation and therapeutics","volume":"5","author":"Lu","year":"2003","journal-title":"Curr. Opin. Mol. Ther."},{"key":"10.1016\/j.lfs.2021.119289_bb0955","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1093\/nar\/gki312","article-title":"A systematic analysis of the silencing effects of an active siRNA at all single-nucleotide mismatched target sites","volume":"33","author":"Du","year":"2005","journal-title":"Nucleic Acids Res."},{"issue":"4","key":"10.1016\/j.lfs.2021.119289_bb0960","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/gm149","article-title":"Progress in the use of RNA interference as a therapy for chronic hepatitis B virus infection","volume":"2","author":"Weinberg","year":"2010","journal-title":"Genome Medicine"},{"key":"10.1016\/j.lfs.2021.119289_bb0965","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/nrd2742","article-title":"Knocking down barriers: advances in siRNA delivery","volume":"8","author":"Whitehead","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.lfs.2021.119289_bb0970","doi-asserted-by":"crossref","first-page":"498","DOI":"10.3390\/pharmaceutics5030498","article-title":"Advances in lipid nanoparticles for siRNA delivery","volume":"5","author":"Tam","year":"2013","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.lfs.2021.119289_bb0975","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.nbt.2013.10.001","article-title":"Cationic lipid nanosystems as carriers for nucleic acids","volume":"31","author":"Cortesi","year":"2014","journal-title":"New Biotechnol."},{"key":"10.1016\/j.lfs.2021.119289_bb0980","first-page":"570","article-title":"FDA approves patisiran to treat hereditary transthyretin amyloidosis","volume":"14","author":"Wood","year":"2018","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.lfs.2021.119289_bb0985","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1038\/s41565-019-0591-y","article-title":"The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs","volume":"14","author":"Akinc","year":"2019","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.lfs.2021.119289_bb0990","doi-asserted-by":"crossref","first-page":"8529","DOI":"10.1002\/anie.201203263","article-title":"Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo","volume":"51","author":"Jayaraman","year":"2012","journal-title":"Angew. Chem. Int. Ed."},{"issue":"6","key":"10.1016\/j.lfs.2021.119289_bb0995","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.jhep.2007.06.015","article-title":"Liver target delivery of small interfering RNA to the HCV gene by lactosylated cationic liposome","volume":"47","author":"Watanabe","year":"2007","journal-title":"J. Hepatol."},{"issue":"1\u201317","key":"10.1016\/j.lfs.2021.119289_bb1000","first-page":"161794","article-title":"Lipid nanoparticles as carriers for RNAi against viral infections: current status and future perspectives","volume":"2014","author":"Torrecilla","year":"2014","journal-title":"Biomed. Res. Int."},{"issue":"7552","key":"10.1016\/j.lfs.2021.119289_bb1005","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/nature14442","article-title":"Lipid nanoparticle siRNA treatment of Ebola virus Makona infected nonhuman primates","volume":"521","author":"Thi","year":"2015","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.lfs.2021.119289_bb1010","doi-asserted-by":"crossref","first-page":"319","DOI":"10.4155\/tde-2016-0006","article-title":"mRNA vaccine delivery using lipid nanoparticles","volume":"7","author":"Reichmuth","year":"2016","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.lfs.2021.119289_bb1015","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1517\/17425247.2014.901308","article-title":"Nucleic acid vaccines: prospects for non-viral delivery of mRNA vaccines","volume":"11","author":"Deering","year":"2014","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.lfs.2021.119289_bb1020","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1016\/j.vaccine.2018.01.029","article-title":"Multi-antigenic human cytomegalovirus mRNA vaccines that elicit potent humoral and cell-mediated immunity","volume":"36","author":"John","year":"2018","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.lfs.2021.119289_bb1025","first-page":"1","article-title":"Optimization of lipid nanoparticles for intramuscular administration of mRNA vaccines","volume":"15","author":"Hassett","year":"2019","journal-title":"Molecular Therapy: Nucleic Acids"},{"key":"10.1016\/j.lfs.2021.119289_bb1030","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1016\/j.celrep.2018.02.014","article-title":"A single administration of CRISPR\/Cas9 lipid nanoparticles achieves robust and persistent in vivo genome editing","volume":"22","author":"Finn","year":"2018","journal-title":"Cell Rep."},{"issue":"108","key":"10.1016\/j.lfs.2021.119289_bb1035","first-page":"1","article-title":"Nanoparticle-based delivery of CRISPR\/Cas9 genome-editing therapeutics","volume":"20","author":"Givens","year":"2018","journal-title":"AAPS J."},{"key":"10.1016\/j.lfs.2021.119289_bb1040","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/biot.201400529","article-title":"CRISPR genome engineering and viral gene delivery: a case of mutual attraction","volume":"10","author":"Schmidt","year":"2015","journal-title":"Biotechnol. J."},{"key":"10.1016\/j.lfs.2021.119289_bb1045","first-page":"1","article-title":"Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR\u2013Cas gene editing","volume":"1","author":"Cheng","year":"2020","journal-title":"Nat. Nanotechnol."},{"issue":"11","key":"10.1016\/j.lfs.2021.119289_bb1050","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1038\/s41565-019-0567-y","article-title":"Smart cancer nanomedicine: strategic directions to improve translation and exploitation","volume":"14","author":"van der Meel","year":"2019","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.lfs.2021.119289_bb1055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ange.201608450","article-title":"Polymer\u2013lipid nanoparticles for systemic delivery of mRNA to the lungs","volume":"128","author":"Kaczmarek","year":"2016","journal-title":"Angew. Chem."},{"key":"10.1016\/j.lfs.2021.119289_bb1060","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1021\/acs.accounts.9b00368","volume":"52","author":"Kulkarni","year":"2019","journal-title":"Acc. Chem. Res."},{"issue":"45","key":"10.1016\/j.lfs.2021.119289_bb1065","first-page":"44826","article-title":"Direct cytosolic delivery of CRISPR\/Cas9-polyamine-DNA polyplexes","volume":"278","author":"Mout","year":"2003","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.lfs.2021.119289_bb1070","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1039\/C7NR07999K","article-title":"Graphene oxide-mediated Cas9\/sgRNA delivery for efficient genome editing","volume":"10","author":"Yue","year":"2018","journal-title":"Nanoscale"},{"issue":"10","key":"10.1016\/j.lfs.2021.119289_bb1075","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1038\/s41565-019-0539-2","article-title":"A biodegradable nanocapsule delivers a Cas9 ribonucleoprotein complex for in vivo genome editing","volume":"14","author":"Chen","year":"2019","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.lfs.2021.119289_bb1080","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1517\/13543784.15.2.89","article-title":"Antiviral applications of RNAi for coronavirus","volume":"15","author":"Wu","year":"2006","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.lfs.2021.119289_bb1085","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1177\/135965350400900310","article-title":"Prophylactic and therapeutic effects of small interfering RNA targeting SARS-coronavirus","volume":"9","author":"Zheng","year":"2004","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.lfs.2021.119289_bb1090","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1038\/nm1280","article-title":"Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque","volume":"11","author":"Li","year":"2005","journal-title":"Nat. Med."},{"key":"10.1016\/j.lfs.2021.119289_bb1095","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1128\/MMBR.00015-08","article-title":"Mechanisms of severe acute respiratory syndrome pathogenesis and innate immunomodulation","volume":"72","author":"Frieman","year":"2008","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"10.1016\/j.lfs.2021.119289_bb1100","doi-asserted-by":"crossref","first-page":"7197","DOI":"10.3390\/molecules15107197","article-title":"Small interfering RNA effectively inhibits the expression of SARS coronavirus membrane gene at two novel targeting sites","volume":"15","author":"Wang","year":"2010","journal-title":"Molecules"},{"key":"10.1016\/j.lfs.2021.119289_bb1105","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/B978-0-12-801238-3.65782-3","article-title":"Liver disease associated with non-hepatitis viruses","author":"Spengler","year":"2020","journal-title":"Encyclopedia of Gastroenterology"},{"key":"10.1016\/j.lfs.2021.119289_bb1110","first-page":"1","article-title":"Dendrimer-based lipid nanoparticles deliver therapeutic FAH mRNA to normalize liver function and extend survival in a mouse model of Hepatorenal Tyrosinemia type I","author":"Cheng","year":"2018","journal-title":"Adv. Mater."},{"key":"10.1016\/j.lfs.2021.119289_bb1115","first-page":"1","article-title":"Nanotechnology for organ-tunable gene editing","volume":"1","author":"Meel","year":"2020","journal-title":"Nat. Nanotechnol."},{"issue":"452002","key":"10.1016\/j.lfs.2021.119289_bb1120","first-page":"1","article-title":"Artificial intelligence in nanotechnology","volume":"24","author":"Sacha","year":"2013","journal-title":"Nanotechnology"},{"key":"10.1016\/j.lfs.2021.119289_bb1125","doi-asserted-by":"crossref","first-page":"25","DOI":"10.14748\/bmr.v24.19","article-title":"Computational modelling: moonlighting on the neuroscience and medicine","volume":"24","author":"Hassanzadeh","year":"2013","journal-title":"Biomed Rev"},{"key":"10.1016\/j.lfs.2021.119289_bb1130","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jconrel.2018.04.042","article-title":"Ignoring the modeling approaches: towards the shadowy paths in nanomedicine","volume":"280","author":"Hassanzadeh","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.lfs.2021.119289_bb1135","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.lfs.2017.06.001","article-title":"Application of modelling and nanotechnology-based approaches: the emergence of breakthroughs in theranostics of central nervous system disorders","volume":"182","author":"Hassanzadeh","year":"2017","journal-title":"Life Sci."},{"issue":"7","key":"10.1016\/j.lfs.2021.119289_bb1140","doi-asserted-by":"crossref","first-page":"13384","DOI":"10.3390\/molecules200713384","article-title":"Molecular docking and structure-based drug design strategies","volume":"20","author":"Ferreira","year":"2015","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.lfs.2021.119289_bb1145","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-29459-7","article-title":"The structural model of Zika virus RNA-dependent RNA polymerase in complex with RNA for rational design of novel nucleotide inhibitors","volume":"8","author":"\u0160ebera","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.lfs.2021.119289_bb1150","first-page":"333021","article-title":"Rapid therapeutic recommendations in the context of a global public health crisis using translational bioinformatics approaches: a proof-of-concept study using Nipah virus infection","author":"Shameer","year":"2018","journal-title":"bioRxiv"},{"issue":"1","key":"10.1016\/j.lfs.2021.119289_bb1155","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1039\/C4NP00085D","article-title":"Antiviral drug discovery: broad-spectrum drugs from nature","volume":"32","author":"Martinez","year":"2015","journal-title":"Nat. Prod. Rep."},{"key":"10.1016\/j.lfs.2021.119289_bb1160","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1600-0668.2006.00452.x","article-title":"Identification of contaminant sources in enclosed environments by inverse CFD modeling","volume":"17","author":"Zhang","year":"2007","journal-title":"Indoor Air"},{"key":"10.1016\/j.lfs.2021.119289_bb1165","doi-asserted-by":"crossref","first-page":"6019","DOI":"10.1016\/j.atmosenv.2011.07.049","article-title":"Impact of scaling and body movement on contaminant transport in airliner cabins","volume":"45","author":"Mazumdar","year":"2011","journal-title":"Atmos. Environ."},{"key":"10.1016\/j.lfs.2021.119289_bb1170","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/s41597-020-0477-8","article-title":"COVID-19 disease map, building a computational repository of SARS-CoV-2 virus-host interaction mechanisms","volume":"7","author":"Ostaszewski","year":"2020","journal-title":"Scientific Data"},{"year":"2020","series-title":"FBA Reveals Guanylate Kinase as a Potential Target for Antiviral Therapies against SARS-CoV-2 (Version 3)","author":"Renz","key":"10.1016\/j.lfs.2021.119289_bb1175"},{"key":"10.1016\/j.lfs.2021.119289_bb1180","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1093\/bib\/bby024","article-title":"Community-driven roadmap for integrated disease maps","volume":"20","author":"Ostaszewski","year":"2019","journal-title":"Brief. Bioinform."},{"key":"10.1016\/j.lfs.2021.119289_bb1185","first-page":"11","article-title":"Tools for visualization and analysis of molecular networks, pathways, and \u2013omics data","volume":"8","author":"Villaveces","year":"2015","journal-title":"Adv. Appl. Bioinforma. Chem. AABC"},{"issue":"1","key":"10.1016\/j.lfs.2021.119289_bb1190","first-page":"1","article-title":"A biophysical model of CRISPR\/Cas9 activity for rational design of genome editing and gene regulation","author":"Farasat","year":"2016","journal-title":"PLoS Comput. Biol."},{"key":"10.1016\/j.lfs.2021.119289_bb1195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/187221007779814745","article-title":"Medical nanorobot architecture based on nano bioelectronics","volume":"1","author":"Cavalcanti","year":"2007","journal-title":"Recent Pat Nanotechnol"},{"issue":"1","key":"10.1016\/j.lfs.2021.119289_bb1200","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1166\/ajrs.2014.1010","article-title":"Nanorobotic applications in medicine: current proposals and designs","volume":"1","author":"Yamaan Saadeh","year":"2014","journal-title":"Am J Robot Surg"},{"key":"10.1016\/j.lfs.2021.119289_bb1205","first-page":"349","article-title":"Equipment and technology in robotics","volume":"60","author":"Murphy","year":"2007","journal-title":"Arch. Esp. Urol."},{"key":"10.1016\/j.lfs.2021.119289_bb1210","first-page":"37","article-title":"Creation of nanorobots: both state-of-the science and state-of-the-art","volume":"27","author":"Hassanzadeh","year":"2016","journal-title":"Biomedical Reviews"},{"key":"10.1016\/j.lfs.2021.119289_bb1215","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1080\/10611860600612862","article-title":"Nanorobot: A versatile tool in nanomedicine","volume":"14","author":"Patel","year":"2006","journal-title":"J. Drug Target."},{"key":"10.1016\/j.lfs.2021.119289_bb1220","doi-asserted-by":"crossref","first-page":"22650","DOI":"10.1038\/srep22650","article-title":"A remote-controlled generation of gold@polydopamine (core@ shell) nanoparticles via physical-chemical stimuli of polydopamine\/gold composites","volume":"6","author":"Lee","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.lfs.2021.119289_bb1225","doi-asserted-by":"crossref","first-page":"340","DOI":"10.3109\/10929080802551274","article-title":"A computer-assisted protocol for endovascular target interventions using a clinical MRI system for controlling untethered microdevices and future nanorobots","volume":"13","author":"Martel","year":"2008","journal-title":"Comput Aided Surg"},{"key":"10.1016\/j.lfs.2021.119289_bb1230","doi-asserted-by":"crossref","first-page":"4161","DOI":"10.1002\/anie.201100115","article-title":"Micromachine-enabled capture and isolation of cancer cells in complex media","volume":"50","author":"Balasubramanian","year":"2011","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.lfs.2021.119289_bb1235","first-page":"15","article-title":"Nanorobotics ideas in nanomedicine","volume":"3","author":"Patel","year":"2013","journal-title":"Asian J Pharm Sci Res"},{"key":"10.1016\/j.lfs.2021.119289_bb1240","first-page":"2497","article-title":"Interventional procedure based on nanorobots propelled and steered by flagellated magnetotactic bacteria for direct targeting of tumors in the human body","volume":"2008","author":"Martel","year":"2008","journal-title":"Conf Proc IEEE Eng Med Biol Soc"},{"key":"10.1016\/j.lfs.2021.119289_bb1245","first-page":"276","article-title":"Nanobots: the future of medical treatments","volume":"4","author":"Somanna","year":"2015","journal-title":"Int J Sci Tech Res"},{"key":"10.1016\/j.lfs.2021.119289_bb1250","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1002\/smll.201400245","article-title":"A DNA origami nanorobot controlled by nucleic acid hybridization","volume":"10","author":"Torelli","year":"2014","journal-title":"Small"},{"key":"10.1016\/j.lfs.2021.119289_bb1255","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1126\/science.1214081","article-title":"A logic-gated nanorobot for targeted transport of molecular payloads","volume":"335","author":"Douglas","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.lfs.2021.119289_bb1260","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1063\/1.2431454","article-title":"Bacterial flagella-based propulsion and on\/off motion control of microscale objects","volume":"90","author":"Behkam","year":"2007","journal-title":"Appl. Phys. Lett."},{"key":"10.1016\/j.lfs.2021.119289_bb1265","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1166\/jctn.2003.003","article-title":"Computational studies of viral protein nano-actuators","volume":"1","author":"Dubey","year":"2004","journal-title":"J Comp Theor Nanosci"},{"key":"10.1016\/j.lfs.2021.119289_bb1270","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1146\/annurev.biochem.69.1.531","article-title":"Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin","volume":"69","author":"Skehel","year":"2000","journal-title":"Annu. Rev. Biochem."},{"issue":"1","key":"10.1016\/j.lfs.2021.119289_bb1275","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11227-006-3845-z","article-title":"A survey on wireless grid computing","volume":"37","author":"Ahuja","year":"2006","journal-title":"J. Supercomput."},{"key":"10.1016\/j.lfs.2021.119289_bb1280","first-page":"199","article-title":"Investigation into the future of RFID in biomedical applications","volume":"5119","author":"Ricciardi","year":"2003","journal-title":"Proc. SPIE - Int. Soc. Opt. Eng."},{"issue":"12","key":"10.1016\/j.lfs.2021.119289_bb1285","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.7150\/ijbs.17421","article-title":"CRISPR-Cas9: from genome editing to cancer research","volume":"12","author":"Chen","year":"2016","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.lfs.2021.119289_bb1290","first-page":"1","article-title":"Nanotechnology based CRISPR\/Cas9 system delivery for genome editing: Progress and prospect","volume":"1","author":"Deng","year":"2019","journal-title":"Nanoresearch"}],"container-title":["Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320521002745?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320521002745?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T20:46:07Z","timestamp":1758401167000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0024320521002745"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":258,"alternative-id":["S0024320521002745"],"URL":"https:\/\/doi.org\/10.1016\/j.lfs.2021.119289","relation":{},"ISSN":["0024-3205"],"issn-type":[{"type":"print","value":"0024-3205"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The significance of bioengineered nanoplatforms against SARS-CoV-2: From detection to genome editing","name":"articletitle","label":"Article Title"},{"value":"Life Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lfs.2021.119289","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"119289"}}